RSLS - ReShape Lifesciences Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
2.9M
Enterprise Value 3
-2.99M
Trailing P/E
N/A
Forward P/E 1
N/A
PEG Ratio (5 yr expected) 1
N/A
Price/Sales (ttm)
0.25
Price/Book (mrq)
N/A
Enterprise Value/Revenue 3
-0.26
Enterprise Value/EBITDA 6
0.23

Trading Information

Stock Price History

Beta (5Y Monthly) 2.15
52-Week Change 3-75.76%
S&P500 52-Week Change 325.78%
52 Week High 348.00
52 Week Low 33.60
50-Day Moving Average 36.05
200-Day Moving Average 37.76

Share Statistics

Avg Vol (3 month) 32.84k
Avg Vol (10 day) 35.27k
Shares Outstanding 5353.79k
Float 124.53k
% Held by Insiders 10.00%
% Held by Institutions 167.13%
Shares Short (Dec 30, 2018) 4N/A
Short Ratio (Dec 30, 2018) 40
Short % of Float (Dec 30, 2018) 40.00%
Short % of Shares Outstanding (Dec 30, 2018) 40.00%
Shares Short (prior month Nov 29, 2018) 41.18k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 21:140
Last Split Date 3Nov 07, 2018

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2018
Most Recent Quarter (mrq)Sep 29, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-123.41%

Management Effectiveness

Return on Assets (ttm)-19.42%
Return on Equity (ttm)-519.68%

Income Statement

Revenue (ttm)11.49M
Revenue Per Share (ttm)69.51
Quarterly Revenue Growth (yoy)43,837.50%
Gross Profit (ttm)442.41k
EBITDA -12.76M
Net Income Avi to Common (ttm)-52.08M
Diluted EPS (ttm)-459.31
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)7.72M
Total Cash Per Share (mrq)21.81
Total Debt (mrq)837k
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)1.17
Book Value Per Share (mrq)-44.27

Cash Flow Statement

Operating Cash Flow (ttm)-19.97M
Levered Free Cash Flow (ttm)-6.64M